Patent ductus arteriosus in a late preterm neonate: think congenital hypopituitarism.
Rui KwanRashida Farhad VasanwalaVijayendra Ranjan BaralPublished in: BMJ case reports (2022)
A late preterm female neonate presented with initial respiratory distress and heart murmur attributed to a haemodynamically significant patent ductus arteriosus (hsPDA) not responding to two courses of ibuprofen. Thyroid function performed for prolonged neonatal jaundice at 3 weeks of life suggested central hypothyroidism. Subsequent adrenocorticotropic hormone stimulation test showing hypocortisolism and MRI revealing adenohypophysis hypoplasia confirmed the diagnosis of congenital hypopituitarism (CH). Commencement of hydrocortisone followed by thyroxine replacement coincided with clinical closure of the hsPDA within 72 hours of treatment. Hypothyroidism and hypocortisolism may have contributed to persistent hsPDA. Thyroid hormone increases cytochrome P450 activity, endothelin-1 and fibronectin expression. Hydrocortisone decreases sensitivity of ductus arteriosus to PGE 2 These mechanisms have been postulated to cause ductal constriction and closure. Our case supports this association. hsPDA in a term and near-term neonate with a protracted disease course or associated midline defects should prompt the clinician to suspect CH (hypothyroidism and/or hypocortisolism).
Keyphrases
- gestational age
- replacement therapy
- preterm birth
- low birth weight
- preterm infants
- room temperature
- poor prognosis
- septic shock
- magnetic resonance imaging
- neuropathic pain
- heart failure
- smoking cessation
- atrial fibrillation
- magnetic resonance
- binding protein
- computed tomography
- long non coding rna
- respiratory tract
- type iii